**PharmLabs** Certificate of Analysis (COA)

Sample Name **15G - Caramel Nebula**

| Delta9 THC **ND** | THCa **ND** | Total THC (THCa * 0.877 + THC) **ND** | Delta8 THC **ND** |
|---|---|---|---|

| | | | |
|---|---|---|---|
| Sample ID **SD260731-028 (143602)** | | Matrix **Edible** | |
| Tested for **Chocolate Tripz** | | | |
| Received **Jul 31, 2026** | Reported **Sep 18, 2026** | | |
| Analyses executed **4AD, CANX, KTM, PSY, TRY, MWA** | Unit Mass (g) **35.045** | Num. of Servings **1** | Serving Size (g) **35.05** |

**Laboratory note**: COA Update: 9/18/26 Test reporting updated to reflect: 4AD, CANX, KTM, PSY, TRY only.

## Cannabinoids (CANx)

Analyzed **Jul 31, 2026** | Instrument **HPLC-VWD** | Method **SOP-001**

The expanded Uncertainty of the Cannabinoids analysis is approximately ∓**7.81**% at the 95% Confidence Level




| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|---|---|---|---|---|---|---|
| 11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND | ND | ND |
| Cannabidiorcin (CBDO) | 0.006 | 0.02 | ND | ND | ND | ND |
| Abnormal Cannabidiorcin (a-CBDO) | 0.013 | 0.038 | ND | ND | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) | 0.015 | 0.045 | ND | ND | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.015 | 0.045 | ND | ND | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.033 | 0.16 | ND | ND | ND | ND |
| Cannabigerol Acid (CBGA) | 0.033 | 0.16 | ND | ND | ND | ND |
| Cannabigerol (CBG) | 0.048 | 0.16 | ND | ND | ND | ND |
| Cannabidiol (CBD) | 0.069 | 0.229 | ND | ND | ND | ND |
| 1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD) | 0.008 | 0.026 | ND | ND | ND | ND |
| 1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD) | 0.016 | 0.049 | ND | ND | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.049 | 0.162 | ND | ND | ND | ND |
| Δ8-tetrahydrocannabivarin (Δ8-THCV) | 0.012 | 0.036 | ND | ND | ND | ND |
| Cannabidihexol (CBDH) | 0.014 | 0.042 | ND | ND | ND | ND |
| Tetrahydrocannabutol (Δ9-THCB) | 0.01 | 0.029 | ND | ND | ND | ND |
| Cannabinol (CBN) | 0.047 | 0.16 | ND | ND | ND | ND |
| Cannabidiphorol (CBDP) | 0.016 | 0.049 | ND | ND | ND | ND |
| exo-THC (exo-THC) | 0.016 | 0.8 | ND | ND | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.092 | 0.307 | ND | ND | ND | ND |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.044 | 0.16 | ND | ND | ND | ND |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.8 | ND | ND | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.8 | ND | ND | ND | ND |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.8 | ND | ND | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.8 | ND | ND | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.117 | 0.389 | ND | ND | ND | ND |
| Δ9-Tetrahydrocannabihexol (Δ9-THCH) | 0.02 | 0.061 | ND | ND | ND | ND |
| Cannabinol Acetate (CBNO) | 0.009 | 0.027 | ND | ND | ND | ND |
| 9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa) | 0.063 | 0.065 | ND | ND | ND | ND |
| 9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa) | 0.191 | 0.196 | ND | ND | ND | ND |
| Δ9-Tetrahydrocannabiphorol (Δ9-THCP) | 0.017 | 0.8 | ND | ND | ND | ND |
| Δ8-Tetrahydrocannabiphorol (Δ8-THCP) | 0.041 | 0.8 | ND | ND | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.8 | ND | ND | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.013 | 0.041 | ND | ND | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.8 | ND | ND | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.015 | 0.045 | ND | ND | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.037 | 0.112 | ND | ND | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.031 | 0.093 | ND | ND | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.021 | 0.062 | ND | ND | ND | ND |
| **Total THC** ( THCa * 0.877 + **Δ9THC** ) | | | **ND** | **ND** | **ND** | **ND** |
| **Total THC + Δ8THC + Δ10THC** ( THCa * 0.877 + **Δ9THC** + **Δ8THC** + **Δ10THC** ) | | | **ND** | **ND** | **ND** | **ND** |
| **Total CBD** ( CBDa * 0.877 + **CBD** ) | | | **ND** | **ND** | **ND** | **ND** |
| **Total CBG** ( CBGa * 0.877 + **CBG** ) | | | **ND** | **ND** | **ND** | **ND** |
| **Total HHC** ( 9r-HHC + 9s-HHC ) | | | **ND** | **ND** | **ND** | **ND** |
| **Total Cannabinoids Analyzed** | | | **ND** | **ND** | **ND** | **ND** |

## Kratom (KTM)

Analyzed **Jul 31, 2026** | Instrument **HPLC VWD** | Method **SOP-KTM**

The expanded Uncertainty of the Kratom analysis is approximately ∓**7.81**% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|---|---|---|---|---|---|---|
| 7-hydroxy Mitragynine (7HMG) | 0.008 | 0.025 | ND | ND | ND | ND |
| MGM-15 (MGM) | 0.186 | 0.562 | ND | ND | ND | ND |
| Mitragynine (MITG) | 0.018 | 0.054 | ND | ND | ND | ND |
| Speciogynine (SPEG) | 0.007 | 0.02 | ND | ND | ND | ND |
| Speciociliatine (SPCL) | 0.004 | 0.011 | ND | ND | ND | ND |

UI Unidentified
**ND** Not Detected
N/A Not Applicable
**NT** Not Reported
**LOD** Limit of Detection
**LOQ** Limit of Quantification
**<LOQ** Detected below the limit of quantification
**>ULOL** Above the upper limit of linearity
**mg/g** Milligrams per gram
**ug/g** Micrograms per gram
**ug/kg** Micrograms per kilogram
**EU/mg** Endotoxin units per milligram
**CFU/g** Colony-forming units per gram
**TNTC** Too Numerous to Count

PJLA Testing Acc. #85368

DEA license: RP0611043
ISO/IEC 17025:2017 Acc. 85368
COA version: V2
Generated: Sep 18, 2026 01:57 PM PDT

Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr, Quality Assurance Manager
Fri, 18 Sep 2026 13:57:20 -0700



PharmWare LABORATORY LIMS & ELN

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

## 4AD Tryptamines (4AD)

Analyzed **Jul 31, 2026** | Instrument **HPLC VWD** | Method **SOP-4AD**
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ∓**7.81**% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|---|---|---|---|---|---|---|
| Mescaline (MESC) | 0.19 | 0.584 | ND | ND | ND | ND |
| N-methyl Tryptamine (NMT) | 0.004 | 0.013 | ND | ND | ND | ND |
| 4-Hydroxy-MET (4-HO-MET) | 0.013 | 0.04 | ND | ND | ND | ND |
| n,n Dimethyltryptamine (DMT) | 0.015 | 0.048 | ND | ND | ND | ND |
| Psilacetin (PSLA) | 0.015 | 0.044 | ND | ND | ND | ND |
| 4-Hydroxy-DET (4-HO-DET) | 0.014 | 0.042 | ND | ND | ND | ND |
| 4-Acetoxy-MET (4-AcO-MET) | 0.018 | 0.053 | ND | ND | ND | ND |
| 4-Acetoxy-DET (4-AcO-DET) | 0.004 | 0.011 | ND | ND | ND | ND |
| 4-Bromo-DMP (2C-B) | 0.19 | 0.576 | ND | ND | ND | ND |

## Tryptamine (TRY)

Analyzed **Jul 31, 2026** | Instrument **HPLC VWD** | Method **SOP-TRY**
The expanded Uncertainty of the Tryptamine analysis is approximately ∓**7.81**% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|---|---|---|---|---|---|---|
| Norbaeocystin (NORB) | 0.01 | 0.029 | ND | ND | ND | ND |
| Baeocystin (BAEO) | 0.01 | 0.029 | ND | ND | ND | ND |
| Aeruginascin (AERU) | 0.007 | 0.022 | ND | ND | ND | ND |
| Norpsilocin (NORP) | 0.003 | 0.009 | ND | ND | ND | ND |

## Psilocybin & Psilocin (PSY)

Analyzed **Jul 31, 2026** | Instrument **HPLC VWD** | Method **SOP-PSY**
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ∓**7.81**% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|---|---|---|---|---|---|---|
| Psilocybin (PSCY) | 0.007 | 0.019 | ND | ND | ND | ND |
| Psilocin (PSCI) | 0.003 | 0.009 | ND | ND | ND | ND |

**UI** Unidentified
**ND** Not Detected
**N/A** Not Applicable
**NT** Not Reported
**LOD** Limit of Detection
**LOQ** Limit of Quantification
**<LOQ** Detected below the limit of quantification
**>ULOL** Above the upper limit of linearity
**mg/g** Milligrams per gram
**ug/g** Micrograms per gram
**ug/kg** Micrograms per kilogram
**EU/mg** Endotoxin units per milligram
**CFU/g** Colony-forming units per gram
**TNTC** Too Numerous to Count

PJLA Testing
Acc. #85368

DEA license: RP0611043
ISO/IEC 17025:2017 Acc. 85368
COA version: V2
Generated: Sep 18, 2026 01:57 PM PDT

Scan the QR code to verify authenticity.

Authorized Signature
Brandon Starr
Brandon Starr, Quality Assurance Manager
Fri, 18 Sep 2026 13:57:20 -0700



PharmWare LABORATORY LIMS & ELN

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.